PMID- 28637802 OWN - NLM STAT- MEDLINE DCOM- 20190311 LR - 20211211 IS - 1535-5667 (Electronic) IS - 0161-5505 (Print) IS - 0161-5505 (Linking) VI - 59 IP - 1 DP - 2018 Jan TI - Tumor Uptake of (64)Cu-DOTA-Trastuzumab in Patients with Metastatic Breast Cancer. PG - 38-43 LID - 10.2967/jnumed.117.193888 [doi] AB - The goal of this study was to characterize the relationship between tumor uptake of (64)Cu-DOTA-trastuzumab as measured by PET/CT and standard, immunohistochemistry (IHC)-based, histopathologic classification of human epidermal growth factor receptor 2 (HER2) status in women with metastatic breast cancer (MBC). Methods: Women with biopsy-confirmed MBC and not given trastuzumab for 2 mo or more underwent complete staging, including (18)F-FDG PET/CT. Patients were classified as HER2-positive (HER2+) or -negative (HER2-) based on fluorescence in situ hybridization (FISH)-supplemented immunohistochemistry of biopsied tumor tissue. Eighteen patients underwent (64)Cu-DOTA-trastuzumab injection, preceded in 16 cases by trastuzumab infusion (45 mg). PET/CT was performed 21-25 (day 1) and 47-49 (day 2) h after (64)Cu-DOTA-trastuzumab injection. Radiolabel uptake in prominent lesions was measured as SUV(max) Average intrapatient SUV(max) ((pt)) was compared between HER2+ and HER2- patients. Results: Eleven women were HER2+ (8 immunohistochemistry 3+; 3 immunohistochemistry 2+/FISH amplified), whereas 7 were HER2- (3 immunohistochemistry 2+/FISH nonamplified; 4 immunohistochemistry 1+). Median (pt) for day 1 and day 2 was 6.6 and 6.8 g/mL for HER 2+ and 3.7 and 4.3 g/mL for HER2- patients (P < 0.005 either day). The distributions of (pt) overlapped between the 2 groups, and interpatient variability was greater for HER2+ than HER2- disease (P < 0.005 and 0.001, respectively, on days 1 and 2). Conclusion: By 1 d after injection, uptake of (64)Cu-DOTA-trastuzumab in MBC is strongly associated with patient HER2 status and is indicative of binding to HER2. The variability within and among HER2+ patients, as well as the overlap between the HER2+ and HER2- groups, suggests a role for (64)Cu-DOTA-trastuzumab PET/CT in optimizing treatments that include trastuzumab. CI - (c) 2018 by the Society of Nuclear Medicine and Molecular Imaging. FAU - Mortimer, Joanne E AU - Mortimer JE AD - Department of Medical Oncology and Experimental Therapeutics, City of Hope, Duarte, California jmortimer@coh.org. FAU - Bading, James R AU - Bading JR AD - Department of Medical Oncology and Experimental Therapeutics, City of Hope, Duarte, California. FAU - Park, Jinha M AU - Park JM AD - Department of Radiology, City of Hope, Duarte, California. FAU - Frankel, Paul H AU - Frankel PH AD - Department of Information Sciences, City of Hope, Duarte, California. FAU - Carroll, Mary I AU - Carroll MI AD - Department of Medical Oncology and Experimental Therapeutics, City of Hope, Duarte, California. FAU - Tran, Tri T AU - Tran TT AD - Department of Radiology, City of Hope, Duarte, California. FAU - Poku, Erasmus K AU - Poku EK AD - Department of Cancer Immunotherapy and Tumor Immunology, Beckman Research Institute of the City of Hope, Duarte, California; and. FAU - Rockne, Russell C AU - Rockne RC AD - Department of Information Sciences, City of Hope, Duarte, California. FAU - Raubitschek, Andrew A AU - Raubitschek AA AD - Department of Cancer Immunotherapy and Tumor Immunology, Beckman Research Institute of the City of Hope, Duarte, California; and. FAU - Shively, John E AU - Shively JE AD - Department of Immunology, Beckman Research Institute of the City of Hope, Duarte, California. FAU - Colcher, David M AU - Colcher DM AD - Department of Cancer Immunotherapy and Tumor Immunology, Beckman Research Institute of the City of Hope, Duarte, California; and. LA - eng GR - P30 CA033572/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20170621 PL - United States TA - J Nucl Med JT - Journal of nuclear medicine : official publication, Society of Nuclear Medicine JID - 0217410 RN - 0 (64Cu-DOTA-trastuzumab) RN - 0 (Antibodies, Monoclonal, Humanized) RN - 0 (Organometallic Compounds) RN - EC 2.7.10.1 (ERBB2 protein, human) RN - EC 2.7.10.1 (Receptor, ErbB-2) RN - P188ANX8CK (Trastuzumab) SB - IM EIN - J Nucl Med. 2018 Feb;59(2):346. PMID: 29553697 MH - Adult MH - Aged MH - Antibodies, Monoclonal, Humanized/*metabolism MH - Biological Transport MH - Breast Neoplasms/diagnostic imaging/*metabolism/*pathology MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Metastasis MH - Organometallic Compounds/*metabolism MH - Positron Emission Tomography Computed Tomography MH - Receptor, ErbB-2/metabolism MH - Trastuzumab PMC - PMC5750523 OTO - NOTNLM OT - HER2 OT - PET OT - antibody OT - breast cancer OT - clinical trial EDAT- 2017/06/24 06:00 MHDA- 2019/03/12 06:00 PMCR- 2018/07/01 CRDT- 2017/06/23 06:00 PHST- 2017/03/24 00:00 [received] PHST- 2017/05/31 00:00 [accepted] PHST- 2017/06/24 06:00 [pubmed] PHST- 2019/03/12 06:00 [medline] PHST- 2017/06/23 06:00 [entrez] PHST- 2018/07/01 00:00 [pmc-release] AID - jnumed.117.193888 [pii] AID - 193888 [pii] AID - 10.2967/jnumed.117.193888 [doi] PST - ppublish SO - J Nucl Med. 2018 Jan;59(1):38-43. doi: 10.2967/jnumed.117.193888. Epub 2017 Jun 21.